Research in biologics has become a hot area for many large pharmaceutical companies as expiring patents, a flood of generic drugs, and slowing growth in small-molecule drug pipelines have led to decreasing revenues. Many “big pharma” companies have begun to invest aggressively in new biologics programs, biotech acquisitions, and facilities construction in pursuit of new avenues for robust revenue growth. Growing interest in biologics also affords a risk management strategy providing greater diversity for product portfolios that include both small molecule drugs as well as biologics.
The number of biologics approvals has continued to increase over the last decade and big pharma companies can’t afford to “miss out”. Since biologics are by definition drawn out of a growing understanding of biology, their activity is inherently more predictable and their development times shorter. In addition, biologics appear less susceptible to generic competition, although as new “biosimilars” regulations are enacted and take effect, this advantage may diminish somewhat. And as early biologics themselves approach patent expiration, new drug delivery technologies for peptide and protein drugs have assumed central importance in life-cycle management and product proliferation strategies.
The conference provides its participants with a current look at biologics and projects into its future with discussions regarding developments and challenges in immunogenicity, humanization, drug delivery techniques for biologics, modern vaccine development, antibodies, and novel protein and peptide delivery. Overcoming the issue of the role of biologics in drug discovery and how to improve upon the length of time a drug remains effective in the body, without losing money, will be addressed.
For more information:
Last updated on: 27/08/2010